So up guys, Derek, moreplace, more dates.com.

Today we're going to be talking about LGD4033.

This is going to be the most comprehensive video on the entire internet about it.

The article is already up as well.

I posted it actually back in 2016, I believe, and this is just the updated iteration of the video format.

And it includes all mentionable data from clinical trials including

all preclinical data that's mentionable on animal models as well as the human models

and includes my own anecdotal finding side effect profile efficacy etc you will not find

a more comprehensive video of this on the entire

internet. I guarantee you that. So let's get into it. LGD 4033 is a selective androgen receptor

modulator currently being researched for its potential applications in the clinical treatment of

muscle wasting osteoporosis and other related conditions. LGD is purported to be the most potent SARM currently in clinical trials

with its data exhibiting the most favorable ratio of anabolic relative to endrogenic activity in the body.

So what is it exactly?

It was originally developed by Ligand Pharmaceuticals and it was licensed afterwards to Viking Therapeutics and that's who currently owns the LGD license and it's now officially named VK 5211 under Viking Therapeutics.

So LGD is also commonly referred to as some slang terms on the internet like

Anabolicum and I'm not really sure why because that's actually a brand name for an

Anabolic Endrogenic Steroid known as Quimbalone that was developed by a pharmaceutical company

called Park Davis. So that's like totally unrelated. LGD, as I mentioned, is a selective endrogen receptor

modulator SARM developed to be a potential treatment for a variety of musculoskeletal degenerative

diseases. The main goal of all SARMs essentially boils down to finding the right compound

that provides the same therapeutic benefits of testosterone with improved safety

...